We've come a long way, researchers: How a decade of research is helping lupus patients

Nov 04, 2010

Today, individuals with lupus nephritis benefit from better treatments than a decade ago, according to a review appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The article suggests that patients with the disease can now live full lives without suffering from many treatment-related side effects that plagued them in the past. In the future, patients will likely experience additional benefits from treatment strategies currently being explored in clinical trials.

Individuals with the autoimmune disease systemic erythematosus (SLE) can experience a number of medical complications, such as lupus nephritis, an inflammatory kidney disorder. Lupus affects about 1.4 million persons in the US (particularly women aged 20 to 40 years of age); it can be serious and lead to . Researchers have been vigorously studying therapies for the condition in recent years and made significant advances that have helped affected individuals.

Gerald Appel, MD and Andrew Bomback, MD (Columbia University College of Physicians and Surgeons) recently reviewed the various breakthroughs in lupus nephritis research over the past 10 years. They note that improved classification of different classes of the condition now guide therapy. New treatment regimens use lower doses and shorter treatment durations of intravenous cyclophosphamide, a highly toxic —a change that has reduced treatment-related side effects without sacrificing efficacy. In addition, the less toxic immunosuppressive agent mycophenolate mofetil has emerged as a viable alternative to cyclophosphamide for certain classes of lupus nephritis. Also, combination treatments with multiple agents have provided greater benefits than single drugs for many patients.

New therapies that target specific components of the immune system are also proving useful. For example, rituximab, an antibody that depletes B cells, may induce remissions in some patients with severe lupus nephritis, including those whose condition does not respond to cyclophosphamide or mycophenolate mofetil. Other targeted agents include ocrelizumab and belimumab, which also act on B cells, as well as abatacept, which blocks T cell activation. Finally, recent clinical trials have shown that once a patient is in remission, mycophenolate mofetil and azathioprine are effective for preventing relapses.

"Treatment of lupus nephritis is rapidly changing, becoming safer and more effective," said Dr. Appel. Because the disease still negatively affects many individuals, though, investigators continue to seek out new therapies and new regimens based on old therapies. "The treatment of today is markedly different, and objectively more effective, than it was 10 years ago. The hope and expectation is that a similar claim will be made 10 years hence," the authors wrote.

Explore further: Dutch Ebola doctors 'to be evacuated on Sunday'

More information: The article, entitled "Brief Review: Updates on the Treatment of Lupus Nephritis," will appear online on November 1, 2010, doi:10.1681/ASN.2010050472

add to favorites email to friend print save as pdf

Related Stories

Rituximab reduces kidney inflammation in patients with lupus

Mar 04, 2009

Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Jo ...

Alternative therapy for lupus nephritis

Apr 15, 2009

Lupus is a rare but serious disease that mainly affects women of child-bearing age and occurs when the body's immune system goes awry, damaging a variety of organs. When kidneys are targeted, patients develop lupus nephritis, ...

Kidney transplants generally safe for lupus patients

Nov 02, 2009

Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's ...

Recommended for you

Fourth Sierra Leonean doctor dies from Ebola

13 hours ago

A fourth Sierra Leonean doctor, a woman, died Sunday after contracting the dreaded Ebola virus, a top health official said, while a Dutch charity repatriated two doctors suspected of having been contaminated ...

Dutch Ebola doctors 'to be evacuated on Sunday'

16 hours ago

Two Dutch doctors feared to have contracted the deadly Ebola virus while working in Sierra Leone are set to be flown back to the Netherlands "as soon as possible", the foreign ministry said Saturday.

Glycemic control linked to lumbar surgery complications

Sep 12, 2014

(HealthDay)—For patients with diabetes mellitus (DM) undergoing degenerative lumbar spine surgery, suboptimal glycemic control contributes to increased risk of complications and poor outcomes, according ...

User comments : 0